Cargando…

The Vital Role of (131) I-MIBG in Localization of Paraganglioma at Unusual Sites

Paragangliomas (PGLs) are extra-adrenal neuroendocrine tumors. PGL of the urinary bladder are very rare and commonly present with features of hypertensive crisis, headache, syncope, and other symptoms of sympathetic excess. A few of these tumors are silent at the presentation. Here, we report a case...

Descripción completa

Detalles Bibliográficos
Autores principales:	Singhal, Tejasvini, Singh, Parneet, Veerwal, Hardik, Narayan, Manishi L
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Thieme Medical and Scientific Publishers Pvt. Ltd. 2022
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9436520/ https://www.ncbi.nlm.nih.gov/pubmed/36060086 http://dx.doi.org/10.1055/s-0042-1751054

Ejemplares similares

Utility of Axillary Reverse Mapping (ARM) and Incidence of Metastasis in Arm Draining Lymph Nodes in Patients with Breast Cancer
por: Kumar, Pramit, et al.
Publicado: (2022)

Unusual Presentation of Bladder Paraganglioma: Comparison of (131)I MIBG SPECT/CT and (68)Ga DOTANOC PET/CT
por: Jain, Tarun Kumar, et al.
Publicado: (2016)

Role of Sentinel Lymph Node Drainage Mapping for Localization of Contralateral Lymph Node Metastasis in Locally Advanced Oral Squamous Cell Carcinoma – A Prospective Pilot Study
por: Singh, Parneet, et al.
Publicado: (2023)

Repeated Radionuclide therapy in metastatic paraganglioma leading to the highest reported cumulative activity of (131)I-MIBG
por: Ezziddin, Samer, et al.
Publicado: (2012)

Efficacy and Safety of High-Specific-Activity (131)I-MIBG Therapy in Patients with Advanced Pheochromocytoma or Paraganglioma
por: Pryma, Daniel A., et al.
Publicado: (2019)

Prognostic values of initial responses to low-dose (131)I-MIBG therapy in patients with malignant pheochromocytoma and paraganglioma
por: Wakabayashi, Hiroshi, et al.
Publicado: (2013)

Site-based performance of (131)I-MIBG imaging and (99m)Tc-HYNIC-TOC scintigraphy in the detection of nonmetastatic extra-adrenal paraganglioma
por: Hou, Guozhu, et al.
Publicado: (2021)

Successful Treatment of Coexisting Paraganglioma of the Retroperitoneum and Urinary Bladder by Intermediate-Dose 131I-MIBG Therapy: A Case Report
por: Cai, Yi, et al.
Publicado: (2015)

MON-202 Germline SDHB Exon 1 Deletion Is Associated with Absence of (131)I-metaiodobenzylguanidine (MIBG) Uptake in Malignant Paragangliomas
por: Petenuci, Janaina, et al.
Publicado: (2020)

The use of 131I-MIBG in the imaging of metastatic carcinoid tumours.
por: Jodrell, D. I., et al.
Publicado: (1988)

Sequelae and survivorship in patients treated with (131)I-MIBG therapy
por: Sze, W C C, et al.
Publicado: (2013)

The role of (131)I-metaiodobenzylguanidine (MIBG) therapy in unresectable and compromising localised neuroblastoma
por: Schoot, Reineke A., et al.
Publicado: (2013)

Malignant paragangliomas with succinate dehydrogenase subunit B mutation in a 13-year old child treated successfully with surgery and 131-I-MIBG
por: Chow, Chi Kwan Jasmine, et al.
Publicado: (2013)

(131)I-metaiodobenzylguanidine ((131)I-MIBG) therapy for residual neuroblastoma: a mono-institutional experience with 43 patients
por: Garaventa, A, et al.
Publicado: (1999)

Individualized (131)I-mIBG therapy in the management of refractory and relapsed neuroblastoma
por: George, Sally L., et al.
Publicado: (2016)

Toxicity of upfront (131)I-metaiodobenzylguanidine ((131)I-MIBG) therapy in newly diagnosed neuroblastoma patients: a retrospective analysis
por: Bleeker, Gitta, et al.
Publicado: (2013)

Utility of (123)I-MIBG Standardized Uptake Value in Patients with Refractory Pheochromocytoma and Paraganglioma
por: Wakabayashi, Hiroshi, et al.
Publicado: (2019)

Dual thyroid ectopia: A pictorial case series and review of literature
por: Kumar, Ashok, et al.
Publicado: (2020)

[(177)Lu]Lu-DOTA-TATE and [(131)I]MIBG Phenotypic Imaging-Based Therapy in Metastatic/Inoperable Pheochromocytomas and Paragangliomas: Comparative Results in a Single Center
por: Prado-Wohlwend, Stefan, et al.
Publicado: (2022)

Phase I/II study of (131)I-MIBG with vincristine and 5 days of irinotecan for advanced neuroblastoma
por: DuBois, S G, et al.
Publicado: (2015)

Recurrent malignant pheochromocytoma with unusual omental metastasis: (68)Ga-DOTANOC PET/CT and (131)I-MIBG SPECT/CT scintigraphy findings
por: Arora, Saurabh, et al.
Publicado: (2014)

Iodine-131MIBG SPECT/CT in neuroendocrine tumours: An institutional experience
por: Verma, Priyanka, et al.
Publicado: (2012)

Nothing but NET: A review of norepinephrine transporter expression and efficacy of (131)I-mIBG therapy
por: Streby, Keri A, et al.
Publicado: (2015)

Cutaneous Metastases as Initial Presentation of Lung Carcinoma
por: Sharma, Gaurav, et al.
Publicado: (2021)

Misdiagnosis of Paraganglioma by (123)I-mIBG Without Stable Iodine Blockade of Thyroidal Radioiodine Uptake
por: Chen Cardenas, Stanley M, et al.
Publicado: (2020)

OR25-07 A Multi-Center, Open-Label, Pivotal Phase 2 Study of Azedra® (HSA I-131-MIBG) in Patients with Unresectable, Locally Advanced or Metastatic Pheochromocytoma or Paraganglioma: Updated Long-Term Survival and Safety
por: Jimenez, Camilo, et al.
Publicado: (2020)

I-131 mIBG Scintigraphy Curie Versus SIOPEN Scoring: Prognostic Value in Stage 4 Neuroblastoma
por: Riaz, Saima, et al.
Publicado: (2018)

Addition of (131)I-MIBG to PRRT ((90)Y-DOTATOC) for Personalized Treatment of Selected Patients with Neuroendocrine Tumors
por: Bushnell, David L., et al.
Publicado: (2021)

Metastatic Pheochromocytoma Diagnosed with (131) I-MIBG SPECT/CT Imaging in a Patient with Pathogenic VHL Mutation
por: Vankadari, Kousik, et al.
Publicado: (2022)

Transformation of a nonfunctional paraganglioma with I-123 MIBG scintigraphy correlation: A case report: Notice of Retraction
Publicado: (2016)

Response to targeted radionuclide therapy with [(131)I]MIBG AND [(177)Lu]Lu-DOTA-TATE according to adrenal vs. extra-adrenal primary location in metastatic paragangliomas and pheochromocytomas: A systematic review
por: Prado-Wohlwend, Stefan, et al.
Publicado: (2022)

Imaging of pheochromocytoma and paraganglioma: moving beyond “lumpology” with SSTR, FDG and MIBG molecular imaging
por: Hofman, MS, et al.
Publicado: (2015)

Feasibility and advantage of adding (131)I-MIBG to (90)Y-DOTATOC for treatment of patients with advanced stage neuroendocrine tumors
por: Bushnell, David L, et al.
Publicado: (2014)

(68)Ga-DOTATATE PET/CT Compared with (131)I-MIBG SPECT/CT in the Evaluation of Neural Crest Tumors
por: Shahrokhi, Pezhman, et al.
Publicado: (2020)

Delayed Recurrence of Gall Bladder Cancer as Port-site Metastases with Occult Primary Detected on Fluorodeoxyglucose Positron Emission Tomography-Computed Tomography: A Tale of Two Cases
por: Singh, Parneet, et al.
Publicado: (2023)

Treatment of advanced neuroblastoma: feasibility and therapeutic potential of a novel approach combining 131-I-MIBG and multiple drug chemotherapy
por: Mastrangelo, S, et al.
Publicado: (2001)

Localisation of [131I]MIBG in nude mice bearing SK-N-SH human neuroblastoma xenografts: effect of specific activity.
por: Vaidyanathan, G., et al.
Publicado: (1996)

SUN-345 Safety Analysis of High-Specific-Activity I-131 MIBG (AZEDRA(®)) in Patients with Iobenguane Scan Positive Cancers
por: Jimenez, Camilo, et al.
Publicado: (2019)

EANM Dosimetry Committee series on standard operational procedures for internal dosimetry for (131)I mIBG treatment of neuroendocrine tumours
por: Gear, Jonathan, et al.
Publicado: (2020)

Biochemical Tumor Marker Status and Its Role in Treatment Response in Patients Who Received High-Specific-Activity I-131 MIBG in Advanced Pheochromocytoma and Paraganglioma (PPGL): Results From a Pivotal Phase 2 Clinical Trial
por: Jimenez, Camilo, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_0i5pvrkj9odsh7qdmprqcqvoau